Male breast cancer: It's rare, it's complex, and it's increasingly under the microscope. Amanda Nasrallah, a medical student and delegate at the International Association of Student Surgical Societies, recently shared a summary of her work, delving into the genetic factors that make this disease tick. This isn't just a matter of biology; it's about understanding a disease that affects men, often with different implications than its more common counterpart in women.
Nasrallah's research highlights the crucial roles of genes like BRCA2, CHEK2, PALB2, and others, including MAP2K4, ZNF217, THY1, and SPAG5. These are the key players in the genetic puzzle of male breast cancer (MaleBC).
MaleBC is a rare form of cancer, representing less than 1% of all male tumors. Interestingly, its incidence has been on the rise, mirroring the increase seen in female breast cancer (FBC). While we know that hormonal imbalances, environmental factors, and genetics play a role, the specifics of MaleBC's origins are still being uncovered.
One of the biggest risk factors? A family history of breast cancer, which often points to a genetic predisposition. Mutations in high-penetrance genes like BRCA1 and BRCA2 significantly elevate the risk, while mutations in low-penetrance genes like CHEK2 carry a lower, but still present, risk. But here's where it gets controversial: how do these genetic factors specifically contribute to the development of MaleBC?
Nasrallah's review, focusing on human studies published in English, meticulously examined the role of genetics in MaleBC. The results? BRCA2 mutations are major risk factors. Multi-gene panel testing has revealed other genes that may increase the risk of MaleBC. Research has categorized MaleBC into two main subgroups: luminal M1 and luminal M2. The M1 subtype shows chromosomal abnormalities and gene overexpression related to cellular processes and angiogenesis, while the M2 subtype is characterized by upregulated genes in immune response and estrogen receptor signaling.
Furthermore, unique somatic mutations in genes like MAP2K4 and ZNF217, along with novel genes THY1 and SPAG5, have been linked to cancer growth and metastasis. And this is the part most people miss: MaleBC is molecularly distinct from FBC, lacking many of the same genetic and epigenetic traits. This suggests a unique pathway to the disease. Inherited BRCA1 and BRCA2 mutations account for a significant portion of MaleBC cases, underscoring a strong genetic component. Mutations in PALB2 and CHEK2 also contribute to the risk, highlighting a complex genetic landscape.
The differences in genetic mutations between the luminal subtypes, along with gender-based variations in mutation hotspots, further emphasize the complex interplay between gender and genetic risk factors. Genome-wide association studies (GWAS) have identified specific single nucleotide polymorphisms (SNPs) that increase susceptibility to MaleBC, underlining the genetic framework that distinguishes it from FBC.
In conclusion, the genetic component in MaleBC isn't as clear-cut as in its female counterpart. However, the mutation rates in genes like MAP2K4, ZNF217, BRCA1, and especially BRCA2 are directly linked to a higher incidence of MaleBC, suggesting a solid relationship between the two.
What do you think? Does this information change how you view MaleBC? Do you think we need more research on the genetic basis of this disease? Share your thoughts in the comments below!
